CMRAW
Income statement / Annual
Last year (2022), Comera Life Sciences Holdings, Inc.'s total revenue was $633,102.00,
an increase of 97.95% from the previous year.
In 2022, Comera Life Sciences Holdings, Inc.'s net income was -$18.00 M.
See Comera Life Sciences Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$633,102.00 |
$319,832.00 |
$442,919.00 |
| Cost of Revenue |
$210,390.00
|
$161,008.00
|
$104,407.00
|
| Gross Profit |
$422,712.00
|
$158,824.00
|
$338,512.00
|
| Gross Profit Ratio |
0.67
|
0.5
|
0.76
|
| Research and Development Expenses |
$1.74 M
|
$1.75 M
|
$1.26 M
|
| General & Administrative Expenses |
$10.65 M
|
$3.94 M
|
$1.20 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.65 M
|
$3.94 M
|
$1.20 M
|
| Other Expenses |
$0.00
|
-$76,738.00
|
$2,033.00
|
| Operating Expenses |
$12.39 M
|
$5.69 M
|
$2.47 M
|
| Cost And Expenses |
$12.60 M
|
$5.86 M
|
$2.57 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$20,391.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$93,947.00
|
$88,819.00
|
$89,749.00
|
| EBITDA |
-$17.89 M |
-$5.36 M |
-$2.04 M |
| EBITDA Ratio |
-28.25
|
-17.54
|
-4.6
|
| Operating Income Ratio |
-18.91
|
-17.31
|
-4.8
|
| Total Other Income/Expenses Net |
-$6.03 M
|
$83,850.00
|
$2,033.00
|
| Income Before Tax |
-$18.00 M
|
-$5.45 M
|
-$2.13 M
|
| Income Before Tax Ratio |
-28.44
|
-17.05
|
-4.8
|
| Income Tax Expense |
$0.00
|
-$160,588.00
|
-$116,548.00
|
| Net Income |
-$18.00 M
|
-$5.29 M
|
-$2.13 M
|
| Net Income Ratio |
-28.44
|
-16.54
|
-4.8
|
| EPS |
-1.76 |
-0.28 |
-0.11 |
| EPS Diluted |
-1.76 |
-0.28 |
-0.11 |
| Weighted Average Shares Out |
$10.45 M
|
$19.09 M
|
$19.09 M
|
| Weighted Average Shares Out Diluted |
$10.45 M
|
$19.09 M
|
$19.09 M
|
| Link |
|
|
|
